Production at Syracuse Bio Campus in the United States

Lotte Biologics announced on April 6 that it has signed a contract with a global pharmaceutical company based in Japan for the contract development and manufacturing of an anticancer drug candidate.


Lotte Biologics Signs Contract Development and Manufacturing Agreement for Anticancer Drug with Japanese Pharmaceutical Company View original image

Based on this contract, Lotte Biologics plans to establish a strategic partnership in the development and production of biopharmaceuticals.



The company described this agreement as "the first collaboration based on mutual trust between the two companies" and stated, "We will accelerate efforts to strengthen our competitiveness in the global market, including Japan."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing